Novartis's Triple Whammy: A Wake Up Call for Big Pharma's Risk Taking Ambitions The pharmaceutical industry's love affair with risky bets is getting a reality check courtesy of Novartis's triple whammy of bad news.
The company's stock tanked 9% this week after its del desiran drug failed in a late stage trial, marking the third setback for Novartis in as many weeks.
While some may view these setbacks as isolated incidents, they should serve as a warning to Big Pharma: taking on too much risk can be costly.